Literature DB >> 14514341

Prevalence and natural history of adrenal incidentalomas.

Luisa Barzon1, Nicoletta Sonino, Francesco Fallo, Giorgio Palu, Marco Boscaro.   

Abstract

Clinically silent adrenal masses discovered by imaging studies performed for unrelated reasons, i.e. adrenal incidentalomas, have become a rather common finding in clinical practice. However, only limited studies of incidence, prevalence, and natural history of adrenal incidentalomas are available. A comprehensive review of the literature shows the prevalence of adrenal incidentalomas to be 2.3% at autopsy and 0.5-2% at abdominal computed tomography scan. Most lesions are adrenocortical adenomas at histology, whereas the prevalence of adrenocortical carcinomas is relatively low. The risk of malignancy over time for masses defined as benign at diagnosis is estimated at about 1/1000, even though 5-25% of masses increase in size during follow-up. Hyperfunction develops in about 1.7% of cases and the risk is higher in patients with lesions larger than 3 cm. Cortisol hypersecretion is the most likely disorder that may ensue, and it remains subclinical in about two-thirds of cases. The lack of controlled studies precludes making specific management recommendations. Large perspective controlled studies to define the epidemiology, natural history, and possible associated morbidity of adrenal incidentalomas and their impact on the quality of life of patients are needed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514341     DOI: 10.1530/eje.0.1490273

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  125 in total

1.  Increased risk of cancer in patients with fumarate hydratase germline mutation.

Authors:  H J Lehtonen; M Kiuru; S K Ylisaukko-Oja; R Salovaara; R Herva; P A Koivisto; O Vierimaa; K Aittomäki; E Pukkala; V Launonen; L A Aaltonen
Journal:  J Med Genet       Date:  2005-09-09       Impact factor: 6.318

Review 2.  Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications.

Authors:  S Tsagarakis; D Vassiliadi; N Thalassinos
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

3.  Radiosynthesis of [124I]iodometomidate and biological evaluation using small-animal PET.

Authors:  Herbert Kvaternik; Thomas Wanek; Friedrich Hammerschmidt; Ilse Zolle; Reingard Aigner; Claudia Kuntner
Journal:  Mol Imaging Biol       Date:  2014-06       Impact factor: 3.488

4.  Disappearing adrenal masses.

Authors:  I G Hermsen; M P J Polak; H R Haak
Journal:  Endocrine       Date:  2010-07-11       Impact factor: 3.633

5.  Echocardiographic alterations in patients with non-functioning adrenal incidentaloma.

Authors:  F Ermetici; C Dall'Asta; A E Malavazos; C Coman; L Morricone; V Montericcio; B Ambrosi
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

Review 6.  Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives.

Authors:  Barbara Altieri; Giovanna Muscogiuri; Stavroula A Paschou; Andromachi Vryonidou; Silvia Della Casa; Alfredo Pontecorvi; Martin Fassnacht; Cristina L Ronchi; John Newell-Price
Journal:  Endocrine       Date:  2018-08-02       Impact factor: 3.633

7.  Does IGF-1 play a role in the etiopathogenesis of non-functioning adrenocortical adenoma?

Authors:  C T Bahadir; G C Ecemis; H Atmaca
Journal:  J Endocrinol Invest       Date:  2018-03-14       Impact factor: 4.256

8.  Adrenal incidentaloma in pregnancy: clinical, molecular and immunohistochemical findings.

Authors:  F Fallo; V Pezzi; N Sonino; G Altavilla; L Barzon
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

9.  Two-year follow-up of thirty-two non-functional benign adrenal incidentalomas.

Authors:  H Yilmaz; N B Tütüncü; M Sahin
Journal:  J Endocrinol Invest       Date:  2009-07-14       Impact factor: 4.256

10.  Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.

Authors:  Liem M Phan; Enrique Fuentes-Mattei; Weixin Wu; Guermarie Velazquez-Torres; Kanishka Sircar; Christopher G Wood; Tao Hai; Camilo Jimenez; Gilbert J Cote; Levent Ozsari; Marie-Claude Hofmann; Siyuan Zheng; Roeland Verhaak; Lance Pagliaro; Maria Angelica Cortez; Mong-Hong Lee; Sai-Ching J Yeung; Mouhammed Amir Habra
Journal:  Cancer Res       Date:  2015-08-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.